Skip to main content
. 2022 Aug 14;28(30):4182–4200. doi: 10.3748/wjg.v28.i30.4182

Table 3.

Multivariate time-varying Cox regression analysis for hepatocellular carcinoma and death/transplantation in entire cohort

Variable Hepatocellular carcinoma
Decompensation
Death/transplantation
aHR (95%CI)
P value
aHR (95%CI)
P value
aHR (95%CI)
P value
Model 1
Untreated group Reference - Reference - Reference -
IBT group 0.47 (0.28-0.80) 0.005 0.16 (0.08-0.33) < 0.001 0.28 (0.18-0.43) < 0.001
DAA group 0.58 (0.35-0.96) 0.035 0.12 (0.03-0.33) < 0.001 0.19 (0.10-0.35) < 0.001
Age, yr 1.06 (1.03-1.08) < 0.001 1.00 (0.98-1.03) 0.805 1.05 (1.03-1.06) < 0.001
Male sex 2.50 (1.37-4.55) 0.003 - - 1.70 (1.24-2.33) < 0.001
HCV genotype - - - -
2 Reference -
1 2.25 (1.45-3.48) < 0.001
Others/unknown 1.72 (0.66-4.48) 0.266
Cirrhosis 3.81 (2.38-6.10) < 0.001 9.26 (4.03-21.03) < 0.001 1.88 (1.34-2.64) < 0.001
Ever smoker 1.47 (0.82-2.66) 0.192 - - - -
Alcohol consumption - - - -
None Reference -
Social 1.20 (0.73-1.98) 0.473
Significant 2.20 (1.14-4.24) 0.027
BMI, kg/m2 - - - - 0.94 (0.89-0.99) 0.019
Diabetes mellitus 0.96 (0.59-1.56) 0.872 - - 1.12 (0.77-1.62) 0.563
Albumin, g/dL 0.71 (0.44-1.15) 0.162 0.35 (0.20-0.63) < 0.001 0.36 (0.25-0.51) < 0.001
Total bilirubin, mg/dL 0.95 (0.80-1.12) 0.568 1.03 (0.98-1.08) 0.264 - -
PT, INR 2.66 (1.13-6.24) 0.025 3.32 (1.08-10.19) 0.036 2.34 (1.06-5.16) 0.034
AFP, log10 ng/dL 2.12 (1.48-3.05) < 0.001 1.54 (0.95-2.51) 0.08 1.29 (0.94-1.77) 0.112
Model 2
Untreated or no SVR Reference - Reference - Reference -
SVR 0.41 (0.26-0.65) < 0.001 0.10 (0.04-0.29) < 0.001 0.26 (0.17-0.39) < 0.001
Age, yr 1.06 (1.04- 1.08) < 0.001 1.02 (0.99-1.04) 0.152 1.06 (1.04-1.07) < 0.001
Male sex 2.50 (1.38-4.54) 0.003 - - 1.68 (1.23-2.30) 0.001
HCV genotype - - - -
2 Reference -
1 2.25 (1.45-3.48) < 0.001
Others/unknown 1.57 (0.60-4.09) 0.359
Cirrhosis 3.75 (2.35-6.01) < 0.001 7.54 (3.32-17.15) < 0.001 1.72 (1.23-2.41) 0.002
Ever smoker 1.53 (0.85-2.75) 0.156 - - - -
Alcohol consumption - - - -
None Reference -
Social 1.24 (0.75-2.04) 0.397
Significant 2.69 (1.40-5.16) 0.003
BMI, kg/m2 - - - - 0.94 (0.89-0.99) 0.024
Diabetes mellitus 0.99 (0.61-1.61) 0.959 - - 1.10 (0.76-1.60) 0.612
Albumin, g/dL 0.76 (0.47-1.20) 0.238 0.42 (0.24-0.71) 0.001 0.42 (0.30-0.60) < 0.001
Total bilirubin, mg/dL 0.96 (0.81-1.13) 0.624 1.03 (0.99-1.08) 0.156 - -
PT, INR 2.53 (1.02-6.28) 0.044 4.42 (1.48-13.20) 0.008 2.69 (1.22-5.92) 0.014
AFP, log10 ng/dL 2.10 (1.46-3.02) < 0.001 1.48 (0.90-2.44) 0.12 1.17 (0.86-1.60) 0.32

Total number of patients, 2197; number of hepatocellular carcinomas, 113; number of deaths, 202; number of transplantations, 4; number of decompensations, 69. AFP: Alpha-feto protein; aHR: Adjusted hazard ratio; BMI: Body mass index; CI: Confidence interval; DAA: Direct acting antivirals; HCV: Hepatitis C virus; IBT: Interferon-based therapy; PT: Prothrombin time; SVR: Sustained virologic response.